1343P Adding histology-driven chemotherapy (ChT) to overcome primary resistance to first-line immunotherapy (ICI) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) with PD-L1 ≥50%
| Autor: | De Giglio, A., Zullo, L., Di Federico, A., Cani, M., Aldea, M., Favorito, V., Sadowska, A., Hendriks, L.E., Gorría Puga, T., Mezquita, L., Tabbò, F., Novello, S., Ardizzoni, A., Besse, B., Gelsomino, F. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S850-S850 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|